A Modern Approach to Neuroscience and Brain Health

BrightMinds is harnessing a new generation of highly targeted drugs that will reach a specific patient population that the compounds of today cannot. Targeting patients with major depressive disorder (MDD) resistant to SSRIs, Bright Minds Biosciences drugs have the potential to treat patients with resistant MDD without the side effects of options available today.